MindWalk signs multi-year AI drug discovery deal with Teva Australia
MindWalk (NASDAQ:HYFT) signed a multi-year agreement with Teva Australia covering its AI drug discovery platform, Kalkine reports.
MindWalk
Latest in Drug Discovery & Biology rss
Recursion reports Phase 2 REC-4881 data, new chair, Q3 results
Why it matters: Clinical data from an AI-driven drug pipeline is a key test of the discovery model.
Recursion Pharmaceuticals released Phase 2 REC-4881 trial data and appointed a new board chair alongside Q3 earnings and clinical updates, prompting investor analysis.
RecursionOncology
More: Simply Wall St, Yahoo Finance
Algorae expands pharma portfolio, validates AI drug discovery platform
Algorae expanded its pharmaceutical portfolio and validated its AI drug discovery platform, according to TipRanks.
Algorae
Recursion's AI Drug Discovery Platform Draws Nvidia Investment
Stocks Down Under examines why Nvidia invested in Recursion Pharmaceuticals and whether its AI platform could change drug discovery.
Recursion Pharmaceuticals
nPhase raises $30M to expand AI-native clinical data platform
nPhase raked in $30 million to expand its AI-native clinical data platform.
nPhase
STAT+ looks at biotech startups skipping AI for drug discovery
In AI Prognosis, STAT examines biotech startups that do not believe drug discovery is where AI can make the biggest difference, and where they apply it instead.